- 2 years after diagnosis, 79% of patients with early breast cancer (eBCa) return to work.
- Not returning to work was associated with trastuzumab-containing systemic therapies, serious physical adverse events, severe arm morbidity, and psychiatric illness.
Why this matters
- Patients with breast cancer will want to know the likelihood of failure to return to work and why.
- French multicenter prospective cohort study (CANTO) of 1874 women who were working and who were 5 or more years from retirement (≤57 years).
- The primary outcome was nonreturn to work (non-RTW) 2 years after diagnosis.
- Funding: French Foundation for Cancer; French National Research Agency; others.
- 21.3% of patients were non-RTW at 2 years postdiagnosis.
- Higher odds of non-RTW were associated with:
- Combined chemotherapy-trastuzumab (vs chemotherapy-hormonotherapy): aOR, 2.01 (95% CI, 1.18-3.44).
- Combined chemotherapy-trastuzumab-hormonotherapy (vs chemotherapy-hormonotherapy): aOR, 1.62 (95% CI, 1.10-2.41).
- At least 1 grade ≥3 physical Common Toxicity Criteria Adverse Events (physical CTCAE vs none): aOR, 1.59 (95% CI, 1.15-2.18).
- Severe arm morbidity (vs none): aOR, 1.59 (95% CI, 1.19-2.13).
- Anxiety (vs none): aOR, 1.47 (95% CI, 1.02-2.11).
- Depression (vs none): aOR, 2.29 (95% CI, 1.34-3.91).
- Observational design.